Ionis Pharmaceuticals (IONS) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/01/24
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersenPRNewsWire • 07/31/24
Ionis Pharmaceuticals, Inc. (IONS) HALOS Study of ION582 in Angelman Syndrome - (Transcript)Seeking Alpha • 07/22/24
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: AnalystBenzinga • 07/22/24
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen WrongInvestors Business Daily • 07/22/24
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndromePRNewsWire • 07/22/24
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander diseasePRNewsWire • 07/18/24
Ionis announces webcast to report HALOS study results for ION582 in Angelman syndromePRNewsWire • 07/08/24
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?Zacks Investment Research • 06/25/24
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completedPRNewsWire • 06/25/24
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedemaPRNewsWire • 06/18/24
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedemaPRNewsWire • 05/31/24
New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA)PRNewsWire • 05/23/24